The growth of Viagra and its effect on the medicinal landscape presents a intricate question for shareholders. While the initial sales statistics were remarkable, the exclusivity has lapsed, leading to a Pharma flood of copycat alternatives that are eroding earnings. In addition, the sector is facing difficulties related to population trends and sh